SEOUL-SEMICONDUCTOR
24.5.2017 09:09:07 CEST | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890) — On April 28, 2017, Seoul Semiconductor Europe GmbH (“Seoul”) filed a patent infringement claim in Germany at the District Court of Düsseldorf against Mouser Electronic Inc. (“Mouser), a global electronic components distributor, which it accused of selling Everlight LED products.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170524005266/en/
In its complaint, Seoul asserted that Everlight’s Mid-Power LED products are infringing Seoul’s patent rights. Seoul has sought a permanent injunction, damages, and recall and destruction of the allegedly infringing products.
The asserted patent serves to improve the light extraction performance of LED devices by enhancing internal-reflection efficiency, which has been widely used in mid-power and high-power LEDs.
This patent litigation is the second patent infringement litigation by Seoul or its affiliate affecting Everlight’s LED products. In March 2017, Seoul Semiconductor Co., Ltd. filed a patent infringement claim in Germany, accusing high-power LED products manufactured by Everlight as well as other LED manufacturers. These patent litigations underscore Seoul’s commitment to protecting its intellectual property rights against infringement, including products consisting of mid-power LEDs and high-power LEDs.
In addition to Seoul’s patent infringement actions, Everlight has been implicated in other patent infringement lawsuits as described below. Nam Ki-bum, Vice President of the Research Center at Seoul, said, “Several LED companies have grown rapidly in a short period of time despite a lack of valuable patent portfolios, which is like building a castle on quicksand. There is no underlying foundation for the company’s products. Seoul, however, has been investing 10% of its revenue in research and development for many years to develop innovative technology and strengthen our patent portfolio. To support a fair market that respects intellectual property rights, Seoul will continuously monitor and take action against alleged infringers in any countries where infringement occurs.”
* Reference [source: various media news articles]
| Plaintiff | Defendant | Business Relation | Patented Technology | Courts | State | Link | ||||||
| Nichia | WOFI Leuchten | Everlight subsidiary | phosphor | Düsseldorf District Court, Germany | Nichia won the suit in the court of first instance and the court ruled for an injunction |
http://www.nichia.co.jp/en/about_nichia/2 |
||||||
| Nichia | REGO-Lighting | Used a white LED tube light product by Everlight subsidiary Zenar | phosphor | Düsseldorf District Court, Germany | On Dec. 5, 2016, the appeals court confirmed patent infringement and ruled in favor of Nichia. |
http://www.nichia.co.jp/en/about_nichia/2 |
||||||
| Nichia | Everlight | Everlight | phosphor | Düsseldorf District Court, Germany | On Oct. 24, 2016, the court granted a preliminary injunction. |
http://www.nichia.co.jp/en/about_nichia/2 |
||||||
| Nichia | Tachibana Eletech and E&E Japan | Distributor of blue LEDs manufactured by Everlight in Japan | LED chip | Tokyo District Court, Japan | On Oct. 14, 2016, the court issued an oder ruled for an infringement in favor of Nichia. |
http://www.nichia.co.jp/en/about_nichia/2016 |
||||||
| Nichia | Mouser | Distributor of Everlight products | phosphor | Düsseldorf District Court, Germany | On Oct. 7, 2016, the court granted a preliminary injunction. |
http://www.nichia.co.jp/en/about_nichia/2 |
||||||
| Nichia | Everlight | Everlight | LED Package | The U.S. District Court for the Eastern District of Texas | The Federal Circuit affirmed an infringement of Nichia’s patents. |
http://www.nichia.co.jp/en/about_nichia/20
http://www.ledinside.com/news/2017/5/nic |
||||||
| Nichia | EBV Elektronik GmbH & Co. KG and EBV Management GmbH (both “EBV“) | Distributor of Everlight products | phosphor | Düsseldorf District Court, Germany | Still in progress |
http://www.nichia.co.jp/en/about_nichia http://www.ledinside.com/press/2017/3/nichia _files_patent_infringement_lawsuit_against_ |
||||||
| Nichia | Everlight Electronics (China) and Beijing Ducheng Yiguang Electronic Devices Selling Center | Everlight subsidiary | phosphor | Beijing Intellectual Property Court, China | Still in progress |
http://www.nichia.co.jp/en/about_nichia |
||||||
| Seoul Semiconductor | Mouser | Distributor of Everlight products | High Power LED | Düsseldorf District Court, Germany | Still in progress | |||||||
| Seoul Semiconductor | Mouser | Distributor of Everlight products | Mid Power LED | Düsseldorf District Court, Germany | On April 28, 2017, Seoul filed the lawsuit. | |||||||
About Seoul Semiconductor:
Seoul Semiconductor develops and commercializes light emitting diodes (LEDs) for automotive, general illumination, specialty lighting, and backlighting markets. As the fifth-largest LED manufacturer globally, Seoul Semiconductor holds more than 12,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as Wicop – a simpler structured Package-Free LED which provides market leading color uniformity, cost savings at the fixture level with high lumen density and allows design flexibility; Acrich, the world's leading direct AC LED; Acrich MJT multi-junction technology; a proprietary family of high-voltage LEDs; NanoDriver Series – World’s Smallest 24W DC LED Drivers and nPola, a new LED product based on GaN-substrate technology that achieves over ten times the output of conventional LEDs.
For more information about Seoul Semiconductor, please visit http://www.seoulsemicon.com
# Trademarks: Wicop and Acrich are trademarks of Seoul Semiconductor Co., Ltd.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170524005266/en/
Contact:
Asia
Seoul Semiconductor Co., Ltd
Jake Jung, +82 070.4391.8270
Email:
pr@seoulsemicon.com
or
Europe
Seoul
Semiconductor Europe GmbH
Ariane Heim, +49 (0)89 450 3690-0
Email:
press.eu@seoulsemicon.com
or
North
America
Seoul Semiconductor Inc.
David Cox, +1 (919) 410-9856
Email:
David.cox@seoulsemicon.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom